Why virtual biotechs need a phase-appropriate approach to quality. Explores the "Quality Cursor" concept, outsourcing accountability, and how QMS should evolve alongside the programme — from preclinical through to out-licensing readiness.

An analysis of the evolving Europe–China biotechnology partnership. Explores how European innovation and Chinese biological scale are converging to create a new model for globally integrated drug development — and what quality governance this demands.

An interactive tool for mapping quality maturity across development stages. Explore phase-appropriate quality requirements from pre-clinical through to out-licensing — dynamically adjust and compare your programme's quality posture.

Due diligence engagement performed by QULLA Partners in May 2026 for a major CDMO acquisition. Covering regulatory readiness, quality system maturity, and site-level risk — delivering investor-grade intelligence ahead of a €500–600M transaction.

An upcoming QULLA Partners insight paper exploring the growing role of artificial intelligence tools in GxP audit environments — observations, opportunities, risks, and what quality leaders need to know.